var qadserve_width = "800";var qadserve_height = "440";var qadserve_pid = "9a8dfe4d-99a2-4782-9017-c7cebbe09d4d";var qadserve_skip; 2&l=ur1&category=ce_tradein_iphone&banner=1TXDF1YDARC665JV8FG2&f=ifr&lc=pf4&linkID=ZJDKE46AUWX27BLT" style="border: none;" width="300"> A ,New heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalization by a fifth in keenly awaited study, boosting hopes for a product that is seen as a multimillion-dollar seller . There have been little progress for more than a decade in treating chronic heart failure, in which the heart fails to pump blood around the body. The study compared LCZ696 to an older drug already known to improve survival. The European Society of Cardiology (ESC) has flagged the PARADIGM-HF